B7-H3 expression has previously been shown to limit CD8+ T-cell activation and proliferation, possibly explaining how B7-H3–high tumors in most cancer types are depleted in CD8+ T cells compared with B7-H3–low tumors (38, 39). This evidence concerns the gene CD276 and cancer.